Document is current
Any future updates will be listed below
-
Authors
Torres, Harrys A.
Lok, Anna S.
Suarez-Almazor, Maria E.
Warneke, Carla L.
Kaseb, Ahmed
Miller, Ethan
Sturgis, Erich M.
Foreman, Jessica T.
Angelidakis, Georgios
Ahmed, Sairah
Ferrajoli, Alessandra
Samaniego, Felipe
Hawk, Ernest T.
Hwang, Jessica P.
-
Funding
Funding for this research was provided by:
National Cancer Institute (K07CA132955, R21CA167202)
MD Anderson Cancer Center Clinical Trials Support Resource (P30CA016672)
- License Information
-
More Information
Article History
Received: 11 December 2019
Accepted: 1 April 2020
First Online: 20 April 2020
Compliance with ethical standards
:
: Approved by the Institutional Review Board of The University of Texas MD Anderson Cancer Center.
: Jessica P. Hwang reports grants from Gilead and Merck. Harrys A. Torres is or has been the principal investigator for research grants from Gilead Sciences, Inc., and Merck & Company, Inc., with all funds paid to The University of Texas MD Anderson Cancer Center. He also is or has been a paid scientific advisor for Gilead Sciences, Inc., Merck & Company, Inc., and Dynavax Technologies; the terms of these arrangements are being managed by The University of Texas MD Anderson Cancer Center in accordance with its conflict-of-interest policies. Anna S. Lok reports receiving research grants paid to the University of Michigan from Assembly Biosciences, Bristol-Myers Squibb, Gilead Sciences, and TARGET Pharma Solutions and has served on an advisory board of Gilead Sciences. Maria E. Suarez-Almazor reports receiving consultant fees (≤ 10,000 USD) Pfizer, Inc., AbbVie, Eli Lilly, Agile Therapeutics, and Amag Pharmaceuticals as well as a research grant from the Agency for Health Care Research and Quality. Erich M. Sturgis reports a grant from Roche Diagnostics. All other authors report no conflicts of interest.
